News and Trends 4 Oct 2018 This Year’s Nobel Prizes Highlight Advances in Biotechnology Immune system brakes, optical tweezers, and enzyme evolution. Three separate subjects that span this year’s Nobel Prizes in Physiology or Medicine, Physics and Chemistry. Despite the differences in theory, however, the diverse discoveries have one thing in common: they have applications in the biotechnology industry, Labiotech’s favorite subject. Releasing the immune system’s brakes in cancer […] October 4, 2018 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2018 Algorithm Proves Better Than Humans at Controlling Blood Sugar in Type 1 Diabetes A clinical trial has shown that letting an algorithm decide the amount of insulin a person with type 1 diabetes needs can help keep blood sugar levels under control. The algorithm, being developed at the University of Cambridge, is able to predict how much insulin is needed at each point in time based on the […] October 3, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2018 Septic Shock Drug Shows Promise for Personalized Medicine Septic shock may no longer be as shocking in the future, as a Phase IIa trial brings hope for a personalized immunomodulatory treatment from the French biotech Inotrem. In sepsis, the immune system overreacts to the infection of a pathogen, causing uncontrolled inflammation throughout the body and organ failure. This can lead to septic […] October 2, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2018 Update: Forbion’s Life Science Fund Tops Goal by €90M Update: The European venture capital firm Forbion closed fundraising for it’s fourth life sciences fund at €360M, a much greater amount than the anticipated €250M. The oversubscribed fund is great news for European medical biotech companies, which will be a strong focus for the fund, and shows that there is a strong interest in the […] October 1, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2018 Cancer-Sniffing Diagnostics Company Secures €43.1M Funding Intoxication is not the only condition that we could diagnose with breathalyzers. The UK-US company Owlstone Medical has secured €43.1M funding to help commercialize its tech that ‘smells’ cancer in your breath. Owlstone’s breathalyzer kit diagnoses conditions by measuring volatile organic compounds in a person’s breath. Disease pathologies affect the types and amounts of these […] October 1, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 1 Oct 2018 Could These Innovative Flu Vaccines Prevent Deaths From Deadly Outbreaks? Despite more than a century of scientific endeavour, influenza remains one of the most deadly infectious diseases worldwide. Across Europe, many biotechs are working on novel solutions that could dramatically improve the protection rates offered by current vaccines. Some may even lead to the holy grail of influenza research – a universal flu vaccine. Each […] October 1, 2018 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
More News! 30 Sep 2018 Trouble in the Soil Bed: Sex Toys for Plants We live in a society obsessed with sex. Yet many of us forget that other living beings can have their own issues and needs in the reproductive area. A group of artists and designers from Slovenia got together to create fictional sex toys for the specific problems of plants. A dildo for carnivorous plants and […] September 30, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2018 Roche Acquires UK Cancer Immunotherapy Biotech in Deal Worth up to €655M Tusk Therapeutics has been acquired by Swiss pharma giant Roche, which aims to develop one of its lead immunological cancer treatments. Roche has given Tusk’s shareholders €70M upfront, with up to an additional €585M planned if Tusk achieves certain milestones. Roche seems particularly interested in one of Tusk’s lead programs, an antibody that reduces the […] September 28, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 28 Sep 2018 This Spanish Biotech Helps Personalize Post-Kidney Transplant Care We arrive in the city of Madrid this week to showcase Biohope, which is developing a technique to combat kidney transplant rejection by tailoring immunosuppressant treatments to individual patients. Mission: Founded in 2015, Biohope is developing a commercial lab kit, called Immunobiogram, that predicts the most effective immunosuppressant drugs for kidney transplant patients. Around […] September 28, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2018 Update: Series A Boost Pushes Belgian Microbiome Spin-Off Forward Update (27/09/2018): New investment from Dutch venture capital fund Innovation Industries brings A-Mansia’s Series A round up to €18M. The company’s first human study of the effects of A. muciniphila in volunteers is currently underway at the University of Louvain. Published on 27/04/2018 A-Mansia Biotech has raised €13M in Series A financing led by Seventure Partners. The […] September 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Expert Advice 27 Sep 2018 How to Build an Outstanding Personal Brand in the Biopharma Industry “Your brand is what people say about you when you’re not in the room.” – Jeff Bezos Your personal brand is essentially your professional reputation, publicised. In this crazy century, every individual has become the writer, editor, and creative director of their own publication. The internet has made the wisdom of company branding […] September 27, 2018 - 9 minutesmins - By James Mathison Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2018 Spanish Biotech Raises €21.3M To Advance Rare Disease Pipeline Rare genetic diseases in the central nervous system may be less of a headache in future, as Barcelona-based biotech Minoryx has raised €21.3M in series B fundraising to test its lead drug candidate against other rare neurological conditions. According to Philippe Monteyne, partner at investor Fund+, “it is the largest investment in biotech in Spain […] September 26, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email